104
Views
0
CrossRef citations to date
0
Altmetric
Correspondence

Wilms’ tumor 1 gene expression levels in acute promyelocytic leukemia compared to other acute myeloid leukemia subtypes

&
Pages 498-499 | Received 02 Apr 2015, Accepted 13 Jun 2015, Published online: 18 Jul 2015

References

  • Marlton P. The many facets of WT1 in acute myeloid leukaemia: clarity remains elusive. Leuk Lymphoma 2014;55:235–237.
  • Hecht A, Nolte F, Nowak D, et al. Prognostic importance of expression of the Wilms’ tumor 1 gene in newly diagnosed acute promyelocytic leukemia. Leuk Lymphoma 2015;1–7. doi:10.3109/10428194.2014.990011.
  • Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071–3079.
  • Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997; 89:1405–1412.
  • Candoni A, Tiribelli M, Toffoletti E, et al. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. Eur J Haematol 2009;82:61–68.
  • Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878–2884.
  • Kerst G, Bergold N, Viebahn S, et al. WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase. Leuk Res 2008; 32:1393–1399.
  • Glienke W, Chow KU, Bauer N, et al. Down-regulation of WT1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 2006;47:1629–1638.
  • Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, IARC Press 2008:809–838.
  • Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009; 27:5195–5201.
  • Cilloni D, Gottardi E, De Micheli D, et al.Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 2002;16:2115–2121.
  • Gaur GC, Ramadan SM, Cicconi L, et al. Analysis of mutational status, SNP rs16754, and expression levels of Wilms tumor 1 (WT1) gene in acute promyelocytic leukemia. Ann Hematol 2012;91:1855–1860.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.